Keemotion has developed a motion detection technology. Their proprietary software offers a complete solution for coaches, leagues and broadcasters. Thanks to Keemotion, your organization produces...
VIVES is a multi-sector fund that invests in projects with a positive societal impact
Keemotion has developed a motion detection technology. Their proprietary software offers a complete solution for coaches, leagues and broadcasters. Thanks to Keemotion, your organization produces...
Nuclidium is a clinical-stage biotechnology company specializing in the development of next-generation copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted...
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory diseases. Bionyra’s best-in-class mono and multispecific...
Georges Caron, past CEO Keemotion:
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with the...
Pierre Blondeau, CEO Upstreem:
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Michel Detheux, CEO iTeos Therapeutics:
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to